The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity

• Andersen KG
• Rambaut A
• Lipkin WI
• Holmes EC
• Garry RF

The proximal origin of SARS-CoV-2.

Nat Med. 2020; 26: 450-452

COVID-19 coronavirus pandemic.

• Johns Hopkins University of Medicine

COVID-19 dashboard by the Center for Systems Science and Engineering (CSS) at Johns Hopkins University (JHU).

• Carfì A
• Bernabei R
• Landi F
• Gemelli Against COVID-19 Post-Acute Care Study Group

Persistent symptoms in patients after acute COVID-19.

JAMA. 2020; 324: 603-605

• Helms J
• Kremer S
• Merdji H
• et al.

Neurologic features in severe SARS-CoV-2 infection.

N Engl J Med. 2020; 382: 2268-2270

Long term respiratory complications of covid-19.

BMJ. 2020; 370m3001

• The Editors of the Lancet Group

Learning from a retraction.

Lancet. 2020; 3961056

• Rochwerg B
• Parke R
• Murthy S
• et al.

Misinformation during the coronavirus disease 2019 outbreak: how knowledge emerges from noise.

Crit Care Explor. 2020; 2e0098

The Conversation: Coronavirus research done too fast is testing publishing safeguards, bad science is getting through.

Scientists cut peer-review corners under pressure of COVID-19 pandemic.

• Osuchowski MF
• Aletti F
• Cavaillon JM
• et al.

SARS-CoV-2/COVID-19: evolving reality, global response, knowledge gaps, and opportunities.

Shock. 2020; 54: 416-437

• Centers for Disease Control and Prevention

Frequently asked questions about SARS.

Middle East respiratory syndrome coronavirus (MERS-CoV) – The Kingdom of Saudi Arabia.

• Thoms M
• Buschauer R
• Ameismeier M
• et al.

Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2.

Science. 2020; 369: 1249-1255

Evasion of type I interferon by SARS-CoV-2.

Cell Rep. 2020; 33108234

Mechanisms of SARS-CoV-2 transmission and pathogenesis.

Trends Immunol. 2020; 41: 1100-1115

Detection of SARS-CoV-2 in different types of clinical specimens.

JAMA. 2020; 323: 1843-1844

• Xiao F
• Tang M
• Zheng X
• Liu Y
• Li X
• Shan H

Evidence for gastrointestinal infection of SARS-CoV-2.

Gastroenterology. 2020; 158: 1831-1833.e3

• Stanifer ML
• Kee C
• Cortese M
• et al.

Critical role of type III interferon in controlling SARS-CoV-2 infection in human intestinal epithelial cells.

Cell Rep. 2020; 32107863

• Chu H
• Zhou J
• Wong BH
• et al.

Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response.

Virology. 2014; 454–455: 197-205

• Cheung CY
• Poon LL
• Ng IH
• et al.

Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis.

J Virol. 2005; 79: 7819-7826

Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis.

J Infect Dis. 2014; 209: 1331-1342

• Chen Y
• Feng Z
• Diao B
• et al.

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) directly decimates human spleens and lymph nodes.

medRxiv. 2020; ()

• Wang C
• Xie J
• Zhao L
• et al.

Alveolar macrophage dysfunction and cytokine storm in the pathogenesis of two severe COVID-19 patients.

EBioMedicine. 2020; 57102833

• Wölfel R
• Corman VM
• Guggemos W
• et al.

Virological assessment of hospitalized patients with COVID-2019.

Nature. 2020; 581: 465-469

• Rockx B
• Kuiken T
• Herfst S
• et al.

Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model.

Science. 2020; 368: 1012-1015

• Peiris JSM
• Chu CM
• Cheng VCC
• et al.

Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study.

Lancet. 2003; 361: 1767-1772

• Pan Y
• Zhang D
• Yang P
• Poon LLM
• Wang Q

Viral load of SARS-CoV-2 in clinical samples.

Lancet Infect Dis. 2020; 20: 411-412

Temporal dynamics in viral shedding and transmissibility of COVID-19.

Nat Med. 2020; 26: 672-675

• Corman VM
• Albarrak AM
• Omrani AS
• et al.

Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection.

Clin Infect Dis. 2016; 62: 477-483

• Yilmaz A
• Marklund E
• Andersson M
• et al.

Upper respiratory tract levels of SARS-CoV-2 RNA and duration of viral RNA shedding do not differ between patients with mild and severe/critical COVID-19.

J Infect Dis. 2021; 223: 15-18

• Chandrashekar A
• Liu J
• Martinot AJ
• et al.

SARS-CoV-2 infection protects against rechallenge in rhesus macaques.

Science. 2020; 369: 812-817

• Ni L
• Ye F
• Cheng M-L
• et al.

Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals.

Immunity. 2020; 52: 971-977.e3

• Weis S
• Scherag A
• Baier M
• et al.

Antibody response using six different serological assays in a completely PCR-tested community after a COVID-19 outbreak—the CoNAN study.

Clin Microbiol Infect. 2021; 27: 470.e1-470.e9

• Sekine T
• Perez-Potti A
• Rivera-Ballesteros O
• et al.

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19.

Cell. 2020; 183: 158-168.e14

• Ibarrondo FJ
• Fulcher JA
• Goodman-Meza D
• et al.

Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19.

N Engl J Med. 2020; 383: 1085-1087

• Cao W-C
• Liu W
• Zhang P-H
• Zhang F
• Richardus JH

Disappearance of antibodies to SARS-associated coronavirus after recovery.

N Engl J Med. 2007; 357: 1162-1163

• Tang F
• Quan Y
• Xin ZT
• et al.

Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study.

J Immunol. 2011; 186: 7264-7268

• Wu LP
• Wang NC
• Chang YH
• et al.

Duration of antibody responses after severe acute respiratory syndrome.

Emerg Infect Dis. 2007; 13: 1562-1564

• Guo X
• Guo Z
• Duan C
• et al.

Long-term persistence of IgG antibodies in SARS-CoV infected healthcare workers.

medRxiv. 2020; ()

• Dan JM
• Mateus J
• Kato Y
• et al.

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection.

Science. 2021; 371eabf4063

• Le Bert N
• Tan AT
• Kunasegaran K
• et al.

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls.

Nature. 2020; 584: 457-462

SARS-CoV-2 T cell immunity: specificity, function, durability, and role in protection.

Sci Immunol. 2020; 5eabd6160

• Mateus J
• Grifoni A
• Tarke A
• et al.

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans.

Science. 2020; 370: 89-94

Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC.

J Infect. 2013; 67: 348-350

• Che XY
• Qiu LW
• Liao ZY
• et al.

Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43.

J Infect Dis. 2005; 191: 2033-2037

• Chan KH
• Cheng VC
• Woo PC
• et al.

Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63.

Clin Diagn Lab Immunol. 2005; 12: 1317-1321

• Lv H
• Wu NC
• Tsang OT-Y
• et al.

Cross-reactive antibody response between SARS-CoV-2 and SARS-CoV infections.

Cell Rep. 2020; 31107725

• Premkumar L
• Segovia-Chumbez B
• Jadi R
• et al.

The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.

Sci Immunol. 2020; 5eabc8413

vWei P-F, ed. Diagnosis and treatment protocol for novel coronavirus pneumonia (trial version 7). Chin Med J (Engl) 2020; 133: 1087–95.

• Epidemiology Working Group for NCIP Epidemic Response
• Chinese Center for Disease Control and Prevention

The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China.

Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41: 145-151

• Hou YJ
• Okuda K
• Edwards CE
• et al.

SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract.

Cell. 2020; 182: 429-446.e14

• Tang X
• Du RH
• Wang R
• et al.

Comparison of hospitalized patients with ARDS caused by COVID-19 and H1N1.

Chest. 2020; 158: 195-205

• Ellinghaus D
• Degenhardt F
• Bujanda L
• et al.

Genomewide association study of severe Covid-19 with respiratory failure.

N Engl J Med. 2020; 383: 1522-1534

• Siswanto GM
• Gani M
• Fauzi AR
• et al.

Possible silent hypoxemia in a COVID-19 patient: a case report.

Ann Med Surg (Lond). 2020; 60: 583-586

• Dhont S
• Derom E
• Van Braeckel E
• Depuydt P
• Lambrecht BN

The pathophysiology of ‘happy’ hypoxemia in COVID-19.

Respir Res. 2020; 21: 198

• Guan WJ
• Ni ZY
• Hu Y
• et al.

Clinical characteristics of coronavirus disease 2019 in China.

N Engl J Med. 2020; 382: 1708-1720

• Manning HL
• Schwartzstein RM

Pathophysiology of dyspnea.

N Engl J Med. 1995; 333: 1547-1553

Measuring the ventilatory response to hypoxia.

J Physiol. 2007; 584: 285-293

• Brochard L
• Slutsky A
• Pesenti A

Mechanical ventilation to minimize progression of lung injury in acute respiratory failure.

Am J Respir Crit Care Med. 2017; 195: 438-442

• Tobin MJ
• Laghi F
• Jubran A

Why COVID-19 silent hypoxemia is baffling to physicians.

Am J Respir Crit Care Med. 2020; 202: 356-360

Abnormal pulmonary function in COVID-19 patients at time of hospital discharge.

Eur Respir J. 2020; 552001217

• Lang M
• Som A
• Mendoza DP
• et al.

Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT.

Lancet Infect Dis. 2020; 20: 1365-1366

• Westblade LF
• Brar G
• Pinheiro LC
• et al.

SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19.

Cancer Cell. 2020; 38: 661-671.e2

• Magleby R
• Westblade LF
• Trzebucki A
• et al.

Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019.

Clin Infect Dis. 2020; ()

• Hikmet F
• Méar L
• Edvinsson Å
• Micke P
• Uhlén M
• Lindskog C

The protein expression profile of ACE2 in human tissues.

Mol Syst Biol. 2020; 16e9610

• Hoffmann M
• Kleine-Weber H
• Schroeder S
• et al.

SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor.

Cell. 2020; 181: 271-280.e8

• Dickson RP
• Erb-Downward JR
• Martinez FJ
• Huffnagle GB

The microbiome and the respiratory tract.

Annu Rev Physiol. 2016; 78: 481-504

Airborne transmission of SARS-CoV-2: the world should face the reality.

Environ Int. 2020; 139105730

• Wilson NM
• Norton A
• Young FP
• Collins DW

Airborne transmission of severe acute respiratory syndrome coronavirus-2 to healthcare workers: a narrative review.

Anaesthesia. 2020; 75: 1086-1095

• Cantuti-Castelvetri L
• Ojha R
• Pedro LD
• et al.

Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity.

Science. 2020; 370: 856-860

• Wang S
• Qiu Z
• Hou Y
• et al.

AXL is a candidate receptor for SARS-CoV-2 that promotes infection of pulmonary and bronchial epithelial cells.

Cell Res. 2021; 31: 126-140

• Carsana L
• Sonzogni A
• Nasr A
• et al.

Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study.

Lancet Infect Dis. 2020; 20: 1135-1140

• Hellman U
• Karlsson MG
• Engström-Laurent A
• et al.

Presence of hyaluronan in lung alveoli in severe Covid-19: an opening for new treatment options?.

J Biol Chem. 2020; 295: 15418-15422

• Yao XH
• He ZC
• Li TY
• et al.

Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient.

Cell Res. 2020; 30: 541-543

• Ackermann M
• Verleden SE
• Kuehnel M
• et al.

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19.

N Engl J Med. 2020; 383: 120-128

• Prilutskiy A
• Kritselis M
• Shevtsov A
• et al.

SARS-CoV-2 infection-associated hemophagocytic lymphohistiocytosis.

Am J Clin Pathol. 2020; 154: 466-474

• Nicholls JM
• Poon LL
• Lee KC
• et al.

Lung pathology of fatal severe acute respiratory syndrome.

Lancet. 2003; 361: 1773-1778

• Sorbello M
• El-Boghdadly K
• Di Giacinto I
• et al.

The Italian coronavirus disease 2019 outbreak: recommendations from clinical practice.

Anaesthesia. 2020; 75: 724-732

• Gattinoni L
• Chiumello D
• Caironi P
• et al.

COVID-19 pneumonia: different respiratory treatments for different phenotypes?.

Intensive Care Med. 2020; 46: 1099-1102

• Tobin MJ
• Laghi F
• Jubran A

Caution about early intubation and mechanical ventilation in COVID-19.

Ann Intensive Care. 2020; 10: 78

• Grasselli G
• Tonetti T
• Protti A
• et al.

Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study.

Lancet Respir Med. 2020; 8: 1201-1208

• Gattinoni L
• Marini JJ
• Camporota L

The respiratory drive: an overlooked tile of COVID-19 pathophysiology.

Am J Respir Crit Care Med. 2020; 202: 1079-1080

Pulmonary fibrosis: pathogenesis, etiology and regulation.

Mucosal Immunol. 2009; 2: 103-121

• Quartuccio L
• Semerano L
• Benucci M
• Boissier MC
• De Vita S

Urgent avenues in the treatment of COVID-19: targeting downstream inflammation to prevent catastrophic syndrome.

Joint Bone Spine. 2020; 87: 191-193

A potential treatment of COVID-19 with TGF-β blockade.

Int J Biol Sci. 2020; 16: 1954-1955

• Eapen MS
• Lu W
• Gaikwad AV
• et al.

Endothelial to mesenchymal transition: a precursor to post-COVID-19 interstitial pulmonary fibrosis and vascular obliteration?.

Eur Respir J. 2020; 562003167

Pathology and pathogenesis of severe acute respiratory syndrome.

Am J Pathol. 2007; 170: 1136-1147

• Hui DS
• Joynt GM
• Wong KT
• et al.

Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors.

Thorax. 2005; 60: 401-409

• Herridge MS
• Tansey CM
• Matté A
• et al.

Functional disability 5 years after acute respiratory distress syndrome.

N Engl J Med. 2011; 364: 1293-1304

• Hwang DM
• Chamberlain DW
• Poutanen SM
• Low DE
• Asa SL
• Butany J

Pulmonary pathology of severe acute respiratory syndrome in Toronto.

Mod Pathol. 2005; 18: 1-10

• Guo Y
• Korteweg C
• McNutt MA
• Gu J

Pathogenetic mechanisms of severe acute respiratory syndrome.

Virus Res. 2008; 133: 4-12

• Edler C
• Schröder AS
• Aepfelbacher M
• et al.

Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany.

Int J Legal Med. 2020; 134: 1275-1284

• Barton LM
• Duval EJ
• Stroberg E
• Ghosh S
• Mukhopadhyay S

COVID-19 autopsies, Oklahoma, USA.

Am J Clin Pathol. 2020; 153: 725-733

• Ojha V
• Mani A
• Pandey NN
• Sharma S
• Kumar S

CT in coronavirus disease 2019 (COVID-19): a systematic review of chest CT findings in 4410 adult patients.

Eur Radiol. 2020; 30: 6129-6138

• Yu M
• Liu Y
• Xu D
• Zhang R
• Lan L
• Xu H

Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia.

Korean J Radiol. 2020; 21: 746-755

• Klok FA
• Kruip MJHA
• van der Meer NJM
• et al.

Incidence of thrombotic complications in critically ill ICU patients with COVID-19.

Thromb Res. 2020; 191: 145-147

• Obi AT
• Barnes GD
• Napolitano LM
• Henke PK
• Wakefield TW

Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infection.

J Vasc Surg Venous Lymphat Disord. 2021; 9: 23-35

• Obi AT
• Pannucci CJ
• Nackashi A
• et al.

Validation of the Caprini venous thromboembolism risk assessment model in critically ill surgical patients.

JAMA Surg. 2015; 150: 941-948

• Burkhard-Koren NM
• Haberecker M
• Maccio U
• et al.

Higher prevalence of pulmonary macrothrombi in SARS-CoV-2 than in influenza A: autopsy results from ‘Spanish flu’ 1918/1919 in Switzerland to Coronavirus disease 2019.

J Pathol Clin Res. 2021; 7: 135-143

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China.

JAMA Intern Med. 2020; 180: 934-943

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.

Lancet. 2020; 395: 1054-1062

• Chen T
• Wu D
• Chen H
• et al.

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.

BMJ. 2020; 368m1091

• Goyal P
• Choi JJ
• Pinheiro LC
• et al.

Clinical characteristics of Covid-19 in New York City.

N Engl J Med. 2020; 382: 2372-2374

• Thachil J
• Tang N
• Gando S
• et al.

ISTH interim guidance on recognition and management of coagulopathy in COVID-19.

J Thromb Haemost. 2020; 18: 1023-1026

• Leisman DE
• Ronner L
• Pinotti R
• et al.

Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.

Lancet Respir Med. 2020; 8: 1233-1244

Laboratory abnormalities in patients with COVID-2019 infection.

Clin Chem Lab Med. 2020; 58: 1131-1134

• Jirak P
• Larbig R
• Shomanova Z
• et al.

Myocardial injury in severe COVID-19 is similar to pneumonias of other origin: results from a multicentre study.

ESC Heart Fail. 2021; 8: 37-46

• Mazzoni A
• Salvati L
• Maggi L
• et al.

Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent.

J Clin Invest. 2020; 130: 4694-4703

• Varga Z
• Flammer AJ
• Steiger P
• et al.

Endothelial cell infection and endotheliitis in COVID-19.

Lancet. 2020; 395: 1417-1418

• Bösmüller H
• Traxler S
• Bitzer M
• et al.

The evolution of pulmonary pathology in fatal COVID-19 disease: an autopsy study with clinical correlation.

Virchows Arch. 2020; 477: 349-357

• Schaefer IM
• Padera RF
• Solomon IH
• et al.

In situ detection of SARS-CoV-2 in lungs and airways of patients with COVID-19.

Mod Pathol. 2020; 33: 2104-2114

Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China.

Kidney Int. 2020; 98: 219-227

• Buja LM
• Wolf DA
• Zhao B
• et al.

The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities.

Cardiovasc Pathol. 2020; 48107233

• Sadegh Beigee F
• Pourabdollah Toutkaboni M
• Khalili N
• et al.

Diffuse alveolar damage and thrombotic microangiopathy are the main histopathological findings in lung tissue biopsy samples of COVID-19 patients.

Pathol Res Pract. 2020; 216153228

• Iba T
• Levy JH
• Connors JM
• Warkentin TE
• Thachil J
• Levi M

The unique characteristics of COVID-19 coagulopathy.

Crit Care. 2020; 24: 360

• Copin MC
• Parmentier E
• Duburcq T
• Poissy J
• Mathieu D

Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection.

Intensive Care Med. 2020; 46: 1124-1126

• McGonagle D
• O'Donnell JS
• Sharif K
• Emery P
• Bridgewood C

Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia.

Lancet Rheumatol. 2020; 2: e437-e445

• Arachchillage DJ
• Stacey A
• Akor F
• Scotz M
• Laffan M

Thrombolysis restores perfusion in COVID-19 hypoxia.

Br J Haematol. 2020; 190: e270-e274

• Zhang Y
• Xiao M
• Zhang S
• et al.

Coagulopathy and antiphospholipid antibodies in patients with Covid-19.

N Engl J Med. 2020; 382: e38

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.

JAMA. 2020; 323: 1061-1069

• Botta M
• Tsonas AM
• Pillay J
• et al.

Ventilation management and clinical outcomes in invasively ventilated patients with COVID-19 (PRoVENT-COVID): a national, multicentre, observational cohort study.

Lancet Respir Med. 2021; 9: 139-148

• Sinha P
• Calfee CS
• Cherian S
• et al.

Prevalence of phenotypes of acute respiratory distress syndrome in critically ill patients with COVID-19: a prospective observational study.

Lancet Respir Med. 2020; 8: 1209-1218

• Puelles VG
• Lütgehetmann M
• Lindenmeyer MT
• et al.

Multiorgan and renal tropism of SARS-CoV-2.

N Engl J Med. 2020; 383: 590-592

• Wichmann D
• Sperhake JP
• Lütgehetmann M
• et al.

Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study.

Ann Intern Med. 2020; 173: 268-277

• Gill SE
• Dos Santos CC
• O'Gorman DB
• et al.

Transcriptional profiling of leukocytes in critically ill COVID19 patients: implications for interferon response and coagulation.

Intensive Care Med Exp. 2020; 8: 75

• Deinhardt-Emmer S
• Wittschieber D
• Sanft J
• et al.

Early postmortem mapping of SARS-CoV-2 RNA in patients with COVID-19 and the correlation with tissue damage.

Elife. 2021; 10e60361

• South AM
• Diz DI
• Chappell MC

COVID-19, ACE2, and the cardiovascular consequences.

Am J Physiol Heart Circ Physiol. 2020; 318: H1084-H1090

Mechanisms and treatment of organ failure in sepsis.

Nat Rev Nephrol. 2018; 14: 417-427

• Gupta A
• Madhavan MV
• Sehgal K
• et al.

Extrapulmonary manifestations of COVID-19.

Nat Med. 2020; 26: 1017-1032

• Onofrio L
• Caraglia M
• Facchini G
• Margherita V
• Placido S
• Buonerba C

Toll-like receptors and COVID-19: a two-faced story with an exciting ending.

Future Sci OA. 2020; 6FSO605

• Totura AL
• Whitmore A
• Agnihothram S
• et al.

Toll-like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection.

MBio. 2015; 6: e00638-e00715

• van der Made CI
• Simons A
• Schuurs-Hoeijmakers J
• et al.

Presence of genetic variants among young men with severe COVID-19.

JAMA. 2020; 324: 663-673

• Zhang Q
• Bastard P
• Liu Z
• et al.

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19.

Science. 2020; 370eabd4570

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.

Nat Rev Immunol. 2020; 20: 355-362

• Huang C
• Wang Y
• Li X
• et al.

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Lancet. 2020; 395: 497-506

• Bermejo-Martin JF
• González-Rivera M
• Almansa R
• et al.

Viral RNA load in plasma is associated with critical illness and a dysregulated host response in COVID-19.

Crit Care. 2020; 24: 691

• Sinha P
• Matthay MA
• Calfee CS

Is a “cytokine storm” relevant to COVID-19?.

JAMA Intern Med. 2020; 180: 1152-1154

• Chen X
• Zhao B
• Qu Y
• et al.

Detectable serum severe acute respiratory syndrome coronavirus 2 viral load (RNAemia) is closely correlated with drastically elevated interleukin 6 level in critically ill patients with coronavirus disease 2019.

Clin Infect Dis. 2020; 71: 1937-1942

Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing.

Cell Discov. 2020; 6: 31

Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19.

J Med Virol. 2020; 92: 791-796

• Ruan Q
• Yang K
• Wang W
• Jiang L
• Song J

Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China.

Intensive Care Med. 2020; 46: 846-848

• Balnis J
• Adam AP
• Chopra A
• et al.

Unique inflammatory profile is associated with higher SARS-CoV-2 acute respiratory distress syndrome (ARDS) mortality.

Am J Physiol Regul Integr Comp Physiol. 2021; 320: R250-R257

Clinical and immunologic features in severe and moderate coronavirus disease 2019.

J Clin Invest. 2020; 130: 2620-2629

Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing.

Cell Discov. 2020; 6: 31

• Payen D
• Cravat M
• Maadadi H
• et al.

A longitudinal study of immune cells in severe COVID-19 patients.

Front Immunol. 2020; 11580250

• Giamarellos-Bourboulis EJ
• Netea MG
• Rovina N
• et al.

Complex immune dysregulation in COVID-19 patients with severe respiratory failure.

Cell Host Microbe. 2020; 27: 992-1000.e3

• Carter MJ
• Fish M
• Jennings A
• et al.

Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection.

Nat Med. 2020; 26: 1701-1707

• Feldstein LR
• Rose EB
• Horwitz SM
• et al.

Multisystem inflammatory syndrome in U.S. children and adolescents.

N Engl J Med. 2020; 383: 334-346

• Dufort EM
• Koumans EH
• Chow EJ
• et al.

Multisystem inflammatory syndrome in children in New York State.

N Engl J Med. 2020; 383: 347-358

• Bastard P
• Rosen LB
• Zhang Q
• et al.

Autoantibodies against type I IFNs in patients with life-threatening COVID-19.

Science. 2020; 370eabd4585

• Hadjadj J
• Yatim N
• Barnabei L
• et al.

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.

Science. 2020; 369: 718-724

• Blanco-Melo D
• Nilsson-Payant BE
• Liu WC
• et al.

Imbalanced host response to SARS-CoV-2 drives development of COVID-19.

Cell. 2020; 181: 1036-1045.e9

• Trouillet-Assant S
• Viel S
• Gaymard A
• et al.

Type I IFN immunoprofiling in COVID-19 patients.

J Allergy Clin Immunol. 2020; 146: 206-208.e2

• Galani IE
• Rovina N
• Lampropoulou V
• et al.

Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison.

Nat Immunol. 2021; 22: 32-40

• Lee JS
• Park S
• Jeong HW
• et al.

Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19.

Sci Immunol. 2020; 5eabd1554

• Kox M
• Waalders NJB
• Kooistra EJ
• Gerretsen J
• Pickkers P

Cytokine levels in critically ill patients with COVID-19 and other conditions.

JAMA. 2020; 324: 1565-1567

• Monneret G
• Benlyamani I
• Gossez M
• et al.

COVID-19: What type of cytokine storm are we dealing with?.

J Med Virol. 2021; 93: 197-198

• Zhou Z
• Ren L
• Zhang L
• et al.

Heightened innate immune responses in the respiratory tract of COVID-19 patients.

Cell Host Microbe. 2020; 27: 883-890.e2

• Xiong Y
• Liu Y
• Cao L
• et al.

Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients.

Emerg Microbes Infect. 2020; 9: 761-770

• Ronit A
• Berg RMG
• Bay JT
• et al.

Compartmental immunophenotyping in COVID-19 ARDS: a case series.

J Allergy Clin Immunol. 2021; 147: 81-91

• Carvelli J
• Demaria O
• Vély F
• et al.

Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.

Nature. 2020; 588: 146-150

• Yang L
• Han Y
• Nilsson-Payant BE
• et al.

A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids.

Cell Stem Cell. 2020; 27: 125-136.e7

• Nienhold R
• Ciani Y
• Koelzer VH
• et al.

Two distinct immunopathological profiles in autopsy lungs of COVID-19.

Nat Commun. 2020; 115086

• Toldo S
• Bussani R
• Nuzzi V
• et al.

Inflammasome formation in the lungs of patients with fatal COVID-19.

Inflamm Res. 2021; 70: 7-10

• Li MY
• Li L
• Zhang Y
• Wang XS

Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues.

Infect Dis Poverty. 2020; 9: 45

• Lachmann G
• Knaak C
• Vorderwülbecke G
• et al.

Hyperferritinemia in critically ill patients.

Crit Care Med. 2020; 48: 459-465

• Kyriazopoulou E
• Leventogiannis K
• Norrby-Teglund A
• et al.

Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis.

BMC Med. 2017; 15: 172

• Mesas AE
• Cavero-Redondo I
• Álvarez-Bueno C
• et al.

Predictors of in-hospital COVID-19 mortality: a comprehensive systematic review and meta-analysis exploring differences by age, sex and health conditions.

PLoS One. 2020; 15e0241742

Ferritin in the coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis.

J Clin Lab Anal. 2020; 34e23618

• Masetti C
• Generali E
• Colapietro F
• et al.

High mortality in COVID-19 patients with mild respiratory disease.

Eur J Clin Invest. 2020; 50e13314

• Al-Samkari H
• Karp Leaf RS
• Dzik WH
• et al.

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection.

Blood. 2020; 136: 489-500

• Huet T
• Beaussier H
• Voisin O
• et al.

Anakinra for severe forms of COVID-19: a cohort study.

Lancet Rheumatol. 2020; 2: e393-e400

• Cavalli G
• De Luca G
• Campochiaro C
• et al.

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study.

Lancet Rheumatol. 2020; 2: e325-e331

• Dimopoulos G
• de Mast Q
• Markou N
• et al.

Favorable anakinra responses in severe covid-19 patients with secondary hemophagocytic lymphohistiocytosis.

Cell Host Microbe. 2020; 28: 117-123.e1

• Vasquez-Bonilla WO
• Orozco R
• Argueta V
• et al.

A review of the main histopathological findings in coronavirus disease 2019.

Hum Pathol. 2020; 105: 74-83

• Fardet L
• Galicier L
• Lambotte O
• et al.

Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome.

Arthritis Rheumatol. 2014; 66: 2613-2620

Immune-inflammatory parameters in COVID-19 cases: a systematic review and meta-analysis.

Front Med (Lausanne). 2020; 7: 301

• Kox M
• Frenzel T
• Schouten J
• van de Veerdonk FL
• Koenen HJPM
• Pickkers P

COVID-19 patients exhibit less pronounced immune suppression compared with bacterial septic shock patients.

Crit Care. 2020; 24: 263

• Cugno M
• Meroni PL
• Gualtierotti R
• et al.

Complement activation in patients with COVID-19: a novel therapeutic target.

J Allergy Clin Immunol. 2020; 146: 215-217

• Holter JC
• Pischke SE
• de Boer E
• et al.

Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.

Proc Natl Acad Sci USA. 2020; 117: 25018-25025

• Schuetz P
• Albrich W
• Mueller B

Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future.

BMC Med. 2011; 9: 107

• Tujula B
• Hämäläinen S
• Kokki H
• Pulkki K
• Kokki M

Review of clinical practice guidelines on the use of procalcitonin in infections.

Infect Dis (Lond). 2020; 52: 227-234

• Bao J
• Li C
• Zhang K
• Kang H
• Chen W
• Gu B

Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19.

Clin Chim Acta. 2020; 509: 180-194

Crucial laboratory parameters in COVID-19 diagnosis and prognosis: an updated meta-analysis.

Med Clin (Barc). 2020; 155: 143-151

• van Berkel M
• Kox M
• Frenzel T
• Pickkers P
• Schouten J

Biomarkers for antimicrobial stewardship: a reappraisal in COVID-19 times?.

Crit Care. 2020; 24: 600

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.

Lancet Respir Med. 2020; 8: 475-481

• Apicella M
• Campopiano MC
• Mantuano M
• Mazoni L
• Coppelli A
• Del Prato S

COVID-19 in people with diabetes: understanding the reasons for worse outcomes.

Lancet Diabetes Endocrinol. 2020; 8: 782-792

• Yang JK
• Feng Y
• Yuan MY
• et al.

Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS.

Diabet Med. 2006; 23: 623-628

• Taneera J
• El-Huneidi W
• Hamad M
• Mohammed AK
• Elaraby E
• Hachim MY

Expression profile of SARS-CoV-2 host receptors in human pancreatic islets revealed upregulation of ACE2 in diabetic donors.

Biology (Basel). 2020; 9: E215

COVID-19 and the endocrine system: exploring the unexplored.

J Endocrinol Invest. 2020; 43: 1027-1031

• Zhu L
• She ZG
• Cheng X
• et al.

Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes.

Cell Metab. 2020; 31: 1068-1077.e3

Exploring diseases/traits and blood proteins causally related to expression of ACE2, the putative receptor of SARS-CoV-2: a mendelian randomization analysis highlights tentative relevance of diabetes-related traits.

Diabetes Care. 2020; 43: 1416-1426

• Marshall RJ
• Armart P
• Hulme KD
• et al.

Glycemic variability in diabetes increases the severity of influenza.

MBio. 2020; 11: e02841-e02849

• Nielsen TB
• Pantapalangkoor P
• Yan J
• et al.

Diabetes exacerbates infection via hyperinflammation by signaling through TLR4 and RAGE.

MBio. 2017; 8: e00818-e00917

COVID-19, diabetes mellitus and ACE2: the conundrum.

Diabetes Res Clin Pract. 2020; 162108132

• Busse LW
• Chow JH
• McCurdy MT
• Khanna AK

COVID-19 and the RAAS-a potential role for angiotensin II?.

Crit Care. 2020; 24: 136

• Fosbøl EL
• Butt JH
• Østergaard L
• et al.

Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality.

JAMA. 2020; 324: 168-177

• Han Y
• Runge MS
• Brasier AR

Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors.

Circ Res. 1999; 84: 695-703

• Franco R
• Rivas-Santisteban R
• Serrano-Marín J
• Rodríguez-Pérez AI
• Labandeira-García JL
• Navarro G

SARS-CoV-2 as a factor to disbalance the renin-angiotensin system: a suspect in the case of exacerbated IL-6 production.

J Immunol. 2020; 205: 1198-1206

• Verdecchia P
• Cavallini C
• Spanevello A
• Angeli F

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection.

Eur J Intern Med. 2020; 76: 14-20

• Gebhard C
• Regitz-Zagrosek V
• Neuhauser HK
• Morgan R
• Klein SL

Impact of sex and gender on COVID-19 outcomes in Europe.

Biol Sex Differ. 2020; 11: 29

• Montopoli M
• Zumerle S
• Vettor R
• et al.

Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).

Ann Oncol. 2020; 31: 1040-1045

• Scully EP
• Haverfield J
• Ursin RL
• Tannenbaum C
• Klein SL

Considering how biological sex impacts immune responses and COVID-19 outcomes.

Nat Rev Immunol. 2020; 20: 442-447

Dysregulation of immune response in patients with Coronavirus 2019 (COVID-19) in Wuhan, China.

Clin Infect Dis. 2020; 71: 762-768

• Ma A
• Cheng J
• Yang J
• Dong M
• Liao X
• Kang Y

Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients.

Crit Care. 2020; 24: 288

• Carissimo G
• Xu W
• Kwok I
• et al.

Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19.

Nat Commun. 2020; 115243

• Kuri-Cervantes L
• Pampena MB
• Meng W
• et al.

Comprehensive mapping of immune perturbations associated with severe COVID-19.

Sci Immunol. 2020; 5eabd7114

• Bordoni V
• Sacchi A
• Cimini E
• et al.

An inflammatory profile correlates with decreased frequency of cytotoxic cells in COVID-19.

Clin Infect Dis. 2020; 71: 2272-2275

• Silvin A
• Chapuis N
• Dunsmore G
• et al.

Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19.

Cell. 2020; 182: 1401-1418.e18

• Schulte-Schrepping J
• Reusch N
• Paclik D
• et al.

Severe COVID-19 is marked by a dysregulated myeloid cell compartment.

Cell. 2020; 182: 1419-1440.e23

• Agrati C
• Sacchi A
• Bordoni V
• et al.

Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19).

Cell Death Differ. 2020; 27: 3196-3207

• Brudecki L
• Ferguson DA
• McCall CE
• El Gazzar M

Myeloid-derived suppressor cells evolve during sepsis and can enhance or attenuate the systemic inflammatory response.

Infect Immun. 2012; 80: 2026-2034

• Wilk AJ
• Rustagi A
• Zhao NQ
• et al.

A single-cell atlas of the peripheral immune response in patients with severe COVID-19.

Nat Med. 2020; 26: 1070-1076

• Wang J
• Jiang M
• Chen X
• Montaner LJ

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts.

J Leukoc Biol. 2020; 108: 17-41

• Zuo Y
• Yalavarthi S
• Shi H
• et al.

Neutrophil extracellular traps in COVID-19.

JCI Insight. 2020; 5e138999

• Barnes BJ
• Adrover JM
• Baxter-Stoltzfus A
• et al.

Targeting potential drivers of COVID-19: Neutrophil extracellular traps.

J Exp Med. 2020; 217e20200652

• Carter MJ
• Fish M
• Jennings A
• et al.

Immunophenotyping of circulating leukocytes reveal non-specific activation of innate and adaptive immune systems in multi-system inflammatory syndrome of childhood temporally associated with SARS-Cov-2 infection: descriptive cohort study.

Preprints. 2020; ()

• Payen D
• Cravat M
• Maadadi H
• et al.

A longitudinal study of immune cells in severe COVID-19 patients.

Front Immunol. 2020; 11580250

• Laing AG
• Lorenc A
• Del Molino Del Barrio I
• et al.

A dynamic COVID-19 immune signature includes associations with poor prognosis.

Nat Med. 2020; 26: 1623-1635

• Zhou Y
• Fu B
• Zheng X
• et al.

Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients.

Natl Sci Rev. 2020; 7: 998-1002

• Liao M
• Liu Y
• Yuan J
• et al.

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.

Nat Med. 2020; 26: 842-844

• Sanchez-Cerrillo I
• Landete P
• Aldave B
• et al.

COVID-19 severity associates with pulmonary redistribution of CD1c+ DCs and inflammatory transitional and nonclassical monocytes.

J Clin Invest. 2020; 130: 6290-6300

• Grant RA
• Morales-Nebreda L
• Markov NS
• et al.

Circuits between infected macrophages and T cells in SARS-CoV-2 pneumonia.

Nature. 2021; 590: 635-641

• Leijte GP
• Rimmelé T
• Kox M
• et al.

Monocytic HLA-DR expression kinetics in septic shock patients with different pathogens, sites of infection and adverse outcomes.

Crit Care. 2020; 24: 110

• Torrance HDT
• Longbottom ER
• Vivian ME
• et al.

Post-operative immune suppression is mediated via reversible, Interleukin-10 dependent pathways in circulating monocytes following major abdominal surgery.

PLoS One. 2018; 13e0203795

• Cheron A
• Floccard B
• Allaouchiche B
• et al.

Lack of recovery in monocyte human leukocyte antigen-DR expression is independently associated with the development of sepsis after major trauma.

Crit Care. 2010; 14: R208

• Monneret G
• Lepape A
• Voirin N
• et al.

Persisting low monocyte human leukocyte antigen-DR expression predicts mortality in septic shock.

Intensive Care Med. 2006; 32: 1175-1183

• Kim OY
• Monsel A
• Bertrand M
• Coriat P
• Cavaillon JM
• Adib-Conquy M

Differential down-regulation of HLA-DR on monocyte subpopulations during systemic inflammation.

Crit Care. 2010; 14: R61

• Flohé S
• Lendemans S
• Schade FU
• Kreuzfelder E
• Waydhas C

Influence of surgical intervention in the immune response of severely injured patients.

Intensive Care Med. 2004; 30: 96-102

• Spinetti T
• Hirzel C
• Fux M
• et al.

Reduced monocytic human leukocyte antigen-DR expression indicates immunosuppression in critically ill COVID-19 patients.

Anesth Analg. 2020; 131: 993-999

• Wang F
• Hou H
• Yao Y
• et al.

Systemically comparing host immunity between survived and deceased COVID-19 patients.

Cell Mol Immunol. 2020; 17: 875-877

• Jeannet R
• Daix T
• Formento R
• Feuillard J
• François B

Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression.

Intensive Care Med. 2020; 46: 1769-1771

• Monneret G
• Cour M
• Viel S
• Venet F
• Argaud L

Coronavirus disease 2019 as a particular sepsis: a 2-week follow-up of standard immunological parameters in critically ill patients.

Intensive Care Med. 2020; 46: 1764-1765

• Remy S
• Gossez M
• Belot A
• et al.

Massive increase in monocyte HLA-DR expression can be used to discriminate between septic shock and hemophagocytic lymphohistiocytosis-induced shock.

Crit Care. 2018; 22: 213

• Le Tulzo Y
• Pangault C
• Amiot L
• et al.

Monocyte human leukocyte antigen-DR transcriptional downregulation by cortisol during septic shock.

Am J Respir Crit Care Med. 2004; 169: 1144-1151

The CD8 T cell response to respiratory virus infections.

Front Immunol. 2018; 9: 678

Decreased T cell populations contribute to the increased severity of COVID-19.

Clin Chim Acta. 2020; 508: 110-114

As plain as the nose on your face: the case for a nasal (mucosal) route of vaccine administration for Covid-19 disease prevention.

Front Immunol. 2020; 11591897

• Chen R
• Sang L
• Jiang M
• et al.

Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China.

J Allergy Clin Immunol. 2020; 146: 89-100

• Jiang M
• Guo Y
• Luo Q
• et al.

T-cell subset counts in peripheral blood can be used as discriminatory biomarkers for diagnosis and severity prediction of coronavirus disease 2019.

J Infect Dis. 2020; 222: 198-202

Clinical and immune features of hospitalized pediatric patients with coronavirus disease 2019 (COVID-19) in Wuhan, China.

JAMA Netw Open. 2020; 3e2010895

• De Biasi S
• Meschiari M
• Gibellini L
• et al.

Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia.

Nat Commun. 2020; 113434

• Wang F
• Nie J
• Wang H
• et al.

Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia.

J Infect Dis. 2020; 221: 1762-1769

• Shi H
• Wang W
• Yin J
• et al.

The inhibition of IL-2/IL-2R gives rise to CD8⁺ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia.

Cell Death Dis. 2020; 11: 429

• Hou H
• Zhang B
• Huang H
• et al.

Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.

Clin Exp Immunol. 2020; 201: 76-84

• Luo M
• Liu J
• Jiang W
• Yue S
• Liu H
• Wei S

IL-6 and CD8+ T cell counts combined are an early predictor of in-hospital mortality of patients with COVID-19.

JCI Insight. 2020; 5e139024

• Urra JM
• Cabrera CM
• Porras L
• Ródenas I

Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic inflammation in COVID-19 patients.

Clin Immunol. 2020; 217108486

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients.

EBioMedicine. 2020; 55102763

• Wang F
• Hou H
• Luo Y
• et al.

The laboratory tests and host immunity of COVID-19 patients with different severity of illness.

JCI Insight. 2020; 5e137799

• Remy KE
• Mazer M
• Striker DA
• et al.

Severe immunosuppression and not a cytokine storm characterizes COVID-19 infections.

JCI Insight. 2020; 5e140329

• Gimenez E
• Albert E
• Torres I
• et al.

SARS-CoV-2-reactive interferon-gamma-producing CD8+ T cells in patients hospitalized with coronavirus disease 2019.

J Med Virol. 2021; 93: 375-382

• Grifoni A
• Weiskopf D
• Ramirez SI
• et al.

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.

Cell. 2020; 181: 1489-1501.e15

• Schaller T
• Hirschbühl K
• Burkhardt K
• et al.

Postmortem examination of patients with COVID-19.

JAMA. 2020; 323: 2518-2520

• Fajnzylber J
• Regan J
• Coxen K
• et al.

SARS-CoV-2 viral load is associated with increased disease severity and mortality.

Nat Commun. 2020; 115493

• Rouzé A
• Martin-Loeches I
• Povoa P
• et al.

Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study.

Intensive Care Med. 2021; 47: 188-198

• Scharenberg M
• Vangeti S
• Kekäläinen E
• et al.

Influenza A virus infection induces hyperresponsiveness in human lung tissue-resident and peripheral blood NK cells.

Front Immunol. 2019; 101116

• Björkström NK
• Ljunggren HG
• Michaëlsson J

Emerging insights into natural killer cells in human peripheral tissues.

Nat Rev Immunol. 2016; 16: 310-320

• Jiang Y
• Wei X
• Guan J
• et al.

COVID-19 pneumonia: CD8⁺ T and NK cells are decreased in number but compensatory increased in cytotoxic potential.

Clin Immunol. 2020; 218108516

• Marquardt N
• Kekäläinen E
• Chen P
• et al.

Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69⁻CD56^dim cells.

J Allergy Clin Immunol. 2017; 139: 1321-1330.e4

• Maucourant C
• Filipovic I
• Ponzetta A
• et al.

Natural killer cell immunotypes related to COVID-19 disease severity.

Sci Immunol. 2020; 5eabd6832

• Nielsen SCA
• Yang F
• Jackson KJL
• et al.

Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2.

Cell Host Microbe. 2020; 28 (): 516

• Galson JD
• Schaetzle S
• Bashford-Rogers RJM
• et al.

Deep sequencing of B cell receptor repertoires from COVID-19 patients reveals strong convergent immune signatures.

Front Immunol. 2020; 11605170

• Robbiani DF
• Gaebler C
• Muecksch F
• et al.

Convergent antibody responses to SARS-CoV-2 in convalescent individuals.

Nature. 2020; 584: 437-442

• Zhu Z
• Chakraborti S
• He Y
• et al.

Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.

Proc Natl Acad Sci USA. 2007; 104: 12123-12128

• Zhang H
• Wang G
• Li J
• et al.

Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.

J Virol. 2004; 78: 6938-6945

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells.

Cell. 2020; 182: 73-84.e16

Human neutralizing antibodies elicited by SARS-CoV-2 infection.

Nature. 2020; 584: 115-119

• Quinti I
• Lougaris V
• Milito C
• et al.

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia.

J Allergy Clin Immunol. 2020; 146: 211-213.e4

• Soresina A
• Moratto D
• Chiarini M
• et al.

Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover.

Pediatr Allergy Immunol. 2020; 31: 565-569

• Montero-Escribano P
• Matías-Guiu J
• Gómez-Iglesias P
• Porta-Etessam J
• Pytel V
• Matias-Guiu JA

Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: a case series of 60 patients from Madrid, Spain.

Mult Scler Relat Disord. 2020; 42102185

Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19.

Mult Scler Relat Disord. 2020; 41102135

• Treon SP
• Castillo JJ
• Skarbnik AP
• et al.

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.

Blood. 2020; 135: 1912-1915

In defense of evidence-based medicine for the treatment of COVID-19 acute respiratory distress syndrome.

Ann Am Thorac Soc. 2020; 17: 787-789